VivoSeq
Other

Advanced Stage

0

Pipeline Programs

5

Active Trials

3

Companies Involved

Advanced Stage is an early-stage landscape with 0 programs across 3 companies. The most active players are Johnson & Johnson, Shanghai YingLi Pharmaceutical Co. Ltd., Vertex Pharmaceuticals.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

22

clinical trials

Completed11 · 50%
Active, not recruiting4 · 18%
Terminated2 · 9%
Unknown status2 · 9%
Withdrawn1 · 5%
Recruiting1 · 5%
Other1 · 5%

Trial Activity

22 trials

HD21 for Advanced Stages
Active, not recruiting·UUniversity of Cologne·Phase 3·NCT02661503·1,500 enrolled
HD12 for Advanced Stages
Completed·UUniversity of Cologne·Phase 3·NCT00265031
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)